You are viewing the site in preview mode

Skip to main content

Table 3 Risk factors for ipsi-LLNM in patients with PTC

From: Prediction of ipsilateral lateral cervical lymph node metastasis in papillary thyroid carcinoma: a combined dual-energy CT and thyroid function indicators study

  Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Sex 0.690 0.418–1.139 .147    
Age 0.726 0.454–1.160 .180    
Tg (ng/mL) 2.832 1.837–4.365 .000 2.668 1.590–4.475 .000
Anti-Tg (IU/mL) 2.121 1.386–3.245 .001 2.001 1.202–3.333 .008
Anti-TPO (IU/mL) 1.054 0.693–1.603 .805    
HT 0.738 0.430–1.267 .271    
Nodular goiter 1.018 0.649–1.594 .940    
Volume (cm3) 1.093 1.029–1.161 .004    
Cystic degeneration 1.816 1.190–2.771 .006    
Calcification 1.989 1.298–3.048 .002    
IC IAP (mg/mL) 4.418 2.787–7.004 .000 3.691 2.170–6.278 .000
IC IVP (mg/mL) 2.517 1.640–3.863 .000 2.122 1.271–3.541 .004
ETE 6.350 4.012–10.050 .000 6.335 3.768–10.651 .000
  1. LLNM Lateral lymph node metastasis, PTC Papillary thyroid carcinoma, OR Odds ratio, CI Confidence interval, HT Hashimoto’s thyroiditis, ETE Extrathyroidal extension, IC Iodine concentration, IAP In the arterial phase, IVP In the venous phase
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us